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significantly higher in colorectal cancer patients
than in healthy controls
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Background: The association between alpha-1 antitrypsin (AAT) deficiency and colorectal cancer (CRC) is currently
controversial. The present study compares AAT serum concentrations and gene frequencies between a group of
CRC patients and a control group of healthy unrelated people (HUP).
Methods: 267 CRC subjects (63% males, 72 ± 10 years old) were enlisted from a Hospital Clinic setting in Asturias,
Spain. The HUP group comprised 327 subjects (67% males, mean age 70 ± 7.5 years old) from the same
geographical region. Outcome measures were AAT serum concentrations measured by nephelometry, and AAT
phenotyping characterization by isoelectric focusing.
Results: Significantly higher serum concentrations were found among CRC (208 ± 60) than in HUP individuals
(144 ± 20.5) (p = 0.0001). No differences were found in the phenotypic distribution of the Pi*S and Pi*Z allelic
frequencies (p = 0.639), although the frequency of Pi*Z was higher in CRC (21%) than in HUP subjects (15%).
Conclusions: The only statistically significant finding in this study was the markedly higher AAT serum
concentrations found in CRC subjects compared with HUP controls, irrespective of whether their Pi* phenotype
was normal (Pi*MM) or deficient (Pi*MS, Pi*MZ and Pi*SZ). Although there was a trend towards the more
deficient Pi* phenotype the more advanced the tumor, the results were inconclusive due to the small sample
size. Consequently, more powerful studies are needed to reach firmer conclusions on this matter.
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Human alpha-1 antitrypsin (AAT), also known as alpha1
proteinase inhibitor (α1-Pi) and SERPINA1 (Serine Protease
Inhibitor, group A, member 1), is a circulating glycoprotein
whose main function is to inhibit neutrophil elastase and
other serine proteases in blood and tissues. The AAT gene
has two alleles, which are transmitted from parents to their
children by autosomal co-dominant Mendelian inheritance.
Normal alleles, present in 85-90% of individuals, are
denominated Pi (protease inhibitor) M. Thus, a normal
individual has a Pi*MM genotype. The most prevalent
deficiency alleles are denominated S and Z, and their
prevalence in Caucasian populations ranges from 5-10%* Correspondence: perezholandas@gmail.com
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article, unless otherwise stated.and 1-3%, respectively. Consequently, the vast majority
of genotypes result from combinations of Pi*M, Pi*S
and Pi*Z. The normal genotype, Pi*MM, is present in
about of 85-95% of people and fully expresses AAT;
Pi*MS, Pi*SS, Pi*MZ, Pi*SZ and Pi*ZZ are deficiency
genotypes that are present in the other 5-15%, express-
ing approximately 80, 60, 55, 40 and 15% of AAT,
respectively [1].
Severe AAT deficiency, defined as an AAT serum
level less than 35% of the mean expected value, 50 mg/dL
(measured by nephelometry), 11 μM, or 80 mg/dL (mea-
sured by radial immunodifusion, although this is now
an obsolete technique), is usually associated with Pi*ZZ
genotypes, and less frequently with combinations of Z, S,
and about 45 “rare” or null alleles. Both Pi*S and Pi*Z, and
the rare deficiency alleles MMalton, MDuarte, and
SIiyama produce misfolded proteins that are retainedCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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only cell stress and liver damage, but also, as a result of
polymerization and retention in hepatocytes, blood
and tissue concentrations of AAT that are too low to
provide sufficient protection for tissues against the action
of proteinases [2].
AAT deficiency is a hereditary condition that typically
predisposes to premature onset of chronic obstructive
pulmonary disease (COPD), liver cirrhosis, relapsing
panniculitis, systemic vasculitis, and possibly a range
of inflammatory and neoplastic diseases [1,3]. In addition,
several clinical studies have shown that subjects with AAT
deficiency have an increased risk of developing malignan-
cies, including hepatocellular carcinomas [4,5], lung
cancer [6-9], neoplasms of the urinary bladder [10] and
gallbladder [11], malignant lymphomas [12], and colon
cancers [13,14].
The aim of the present study was to investigate whether
AAT deficiency was more common in patients with
CRC than in healthy subjects from Asturias, a northern
(Cantabrian) coastal region of Spain, with one of the
highest prevalences of AAT deficiency in Europe [15,16],
and a high incidence of CRC [17].
Methods
Type of study
This is a population-based genetic project that was de-
signed as a case-control study comparing CRC patients
with a control group of healthy unrelated people (HUP)
from the central region of Asturias, which has an area of
646 km2 and a population of 78,315 inhabitants, almost all
of whom are Caucasian. The population has not changed
significantly in recent last years, and has been little influ-
enced by interbreeding, devastating natural disasters, wars,
epidemics, or migration. This means that the popoulation
may be assumed to be in Hardy-Weinberg equilibrium,
enabling us to estimate the prevalence of the different
phenotypes of AAT in the population.
Ethics
The project was approved by the Valle del Nalón Hospital
Clinical Research Committee (Decision 1/2008). The study
was carried out according to the Good Clinical Practice
Guidelines of the modified Helsinki declaration. Specific
signed informed consent was obtained from each patient
taking part in the study. Participants confirmed their
willingness to participate in the study and their permission
for researchers to access their medical records.
Data collection
Colorectal cancer cohort
The CRC cohort was recruited from an outpatient hospital
clinic in the VIII Health Care Area of Asturias over four
years (2008-2012). A total of 267 CRC patients were finallyenrolled. Most of these were referred by primary care-
givers to the Gastroenterology Department for diagnostic
purposes and proper management, and from there, some
of them were later referred to outpatient clinics from their
referral hospital, to evaluate the need for surgery or other
types of treatment.
A database was set up containing information from all
patients about their general demographic characteristics,
medical history, and the results of physical examination,
laboratory tests, colon endoscopy, colorectal biopsies,
and various radiological tests. Tumor stage and location
were classified following the Union for International Cancer
Control (UICC) recommendations [18]. When required,
the corresponding author provided genetic counselling to
the AAT-deficient patients and their families.
Control cohort
327 volunteer healthy unrelated people (HUP) from the
VIII Health Care Area were recruited by simple random
sampling. To do this, people were selected from the re-
gion’s municipal census records through the use of
random numbers generated by the R-Sigma statistical
program. To standardize the two series, only people
between 40 and 90 years, 60-70% of them male, were
chosen for possible inclusion. Explanatory letters were
sent to them and their cooperation with the study invited.
We also contacted the primary care services and health
area municipalities to encourage participation by the
potential subjects.
A general clinico-epidemiological questionnaire was
completed by each suitable volunteer. Only healthy
people were allowed to participate in the study, those
with serious diseases being rejected. Blood samples were
most commonly obtained at the Valle del Nalón Hospital
laboratory, but some were collected at the health centres
in the area, according to the participants’ preferences. Be-
sides the measurements related to the subject of the study
(AAT serum concentrations and Pi phenotypes), routine
haematological and biochemical analyses were performed,
and 5-8 aliquots of serum from each person were reserved
to check results when these indicated that it might be ap-
propriate to carry out other studies. Individual letters were
sent to participants with normal analytical results, and Z
allele carriers were contacted in an effort to persuade
them to take part in studies, long-term follow-up and fam-
ily screening.
Serum AAT and Pi system phenotypes
Serum AAT levels were determined in the reference la-
boratory of the Instituto Nacional de Silicosis (Oviedo)
by nephelometry, with an Array™ Protein System autoa-
nalyzer (Beckman Instruments, Brea, California, USA).
The normal range of values in our laboratory is 100-
220 mg/dL.
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de Silicosis by isoelectric focusing (IEF) with a HYDRA-
GEL 18 A1AT isofocusing kit, designed for the qualitative
detection and identification of the different AAT pheno-
types in the electrophoretic patterns of human sera.
The procedure involves IEF in agarose gel performed
in the automatic HYDRASYST system, followed by
immune-fixation with AAT antiserum (SEBIA Hispania
S.A., Barcelona, Spain).
Pi allelic frequency and phenotypic prevalence
Gene frequency is defined as the frequency of all genes
of a particular type, whether occurring in homozygotes
or heterozygotes. The total number of alleles is twice the
number of subjects. Therefore, the gene frequency was
obtained by adding the number of S or Z alleles, and
expressing this total as a fraction of the total number of
Pi alleles in the population (alleles per 1,000 genes of all
Pi types).
The prevalence of each phenotype was calculated as-
suming the population to be in Hardy-Weinberg equi-
librium: p2 + 2pq + q2 = 1 (where p = proportion of the Z
allele, and q = proportion of the S allele). This formula
was used to estimate the prevalence of Z homozygotes
and the SZ heterozygotes [19].
Precision factor score (PFS) of statistical reliability for
each cohort
To assess the statistical reliability of the results, a coefficient
of variation (CV) for Pi*S and Pi*Z frequencies in each co-
hort was calculated. This CV is a measure of the precision
of results from each cohort in terms of the dispersion of
the data around the mean. Its value depends on the number
of alleles studied and on the frequencies of Pi*S and Pi*Z
actually found. The precision is inversely proportional to
the CV. Numerical precision factor scores (PFS) for asses-
sing the statistical quality and precision of each cohort were
generated as follows, from both S and Z CVs:
ZCV ¼ 100 Zul−Zllð Þ4 Zfr ;
and
SCV ¼ 100 Sul−Sllð Þ4 Sfr
The mean CV value was calculated as:
CV
¼ ZCV þ SCV
2
and the numerical PFS was calculated as follows:
PFS ¼ 500 1
CV
(where Sul = 95% CI upper limit of S; Sll = 95% CI lower
limit of S; Zul = Z 95% CI upper limit of Z; Zll = Z 95%
CI calculated lower limit; Sfr = frequency of S; Zfr = fre-
quency of Z. The factor of 500 ensures a PFS value
scaled from 0 to 12). These statistical calculations pro-
vide estimates of the mean, median, standard deviation
and the range of the PFS in each cohort. An appropriate
value of PFS for the Asturias population should be
greater than 8 [20].Statistical analysis
Descriptive statistics were used to tabulate the primary
cohort database. Quantitative variables were expressed
as the mean and standard deviation (SD). The normality
of the distributions of quantitative variables was tested
by the Kolmogorov-Smirnov test. Serum concentrations
were compared using Student’s unpaired samples t-test.
A value of p < 0.05 was considered to be statistically
significant.Results
The CRC cohort consisted of 267 subjects, 63% of whom
were males, with a mean age of 72 years (range: 44-90
years). The control cohort comprised 327 subjects, 67%
of whom were males, with a mean age of 70 years (range:
42-89 years). No significant differences in demographic
features were found (Table 1).
Sample sizes, PFS values, number and types of AAT
alleles, along with Pi*S and Pi*Z gene frequencies, and
prevalences calculated assuming the Hardy-Weinberg
equilibrium for the two cohorts are shown. The frequency
of the severe deficiency allele Pi*Z and the estimated
prevalence of MZ, SZ and ZZ were numerically higher in
CRC patients than in HUP subjects, although the differ-
ences were not statistically significant (Table 2).
We found significant differences in AAT serum con-
centrations between the AAT phenotypes of the studied
cohorts, with notably higher values in CRC patients than
in HUP subjects (p < 0.001) (Table 3).
All cases included in our study were carriers of adeno-
carcinomas. The anatomical location of these cancers,
their TNM stage, the treatment given to each patient, as
well as any deaths and their causes are summarized in
Table 4. CRC patients with the MZ genotype tended to
have more advanced tumors (i.e, Stage III) than did those
of the MM normal genotype (50% vs. 34%). In addition,
60% of MZ patients received postoperative chemotherapy,
whereas only 30% of MM patients did (p = 0.058). 30% of
MZ patients compared with 16% of the MM subgroup
died from causes directly related to the CRC, the differ-
ence not being statistically significant. The analysis of the
remaining descriptive data falls outside the scope of this
study, and is presented for information purposes only.
Table 1 Demographic features found in the general population (control cohort) and in the colorectal cancer cohort
General population, AAT-Pi* genotypes Colorectal cancer, AAT-Pi* genotypes P
Total MM MS MZ SS SZ Total MM MS MZ SS SZ
Genotypes, n (%) 327 (100) 256 (78.3) 60 (18.3) 9 (0.03) 1 (.003) 1 (.003) 267 (100) 207 (77.5) 49 (18.4) 10 (0.04) 0 (0) 1 (0.004) 0.985
Males, n (%) 219 (67) 171 (67) 40 (67) 7 (78) 0 (0) 1 (100) 169 (63) 131 (63) 32 (65) 6 (60) - - 0.712
Age, years [SD] 70.0 [7.5] 69.8 [7.4] 70.5 [7.9] 73.2 [6.4] 65.0 - 80.0 - 72 [9.6] 72.5 [9.8] 72.8 [9.2] 70.2 [8.1] - 81 [NA] 0.713
Familial CRC, n (%) 13 (3.9) 12 (5) 1 (1.7) 0 (0) 0 (0) 0 (0) 11 (4) 10 (5) 1 (2) 0 (0) - 0 (0) 0.590
Alcohol abuse, n (%)* 66 (20) 60 (23) 5 (8) 1 (11) 0 (0) 0 (0) 34 (13) 27 (13) 5 (10) 2 (20) - 0 (0) 0.706
TOB n (%)** 88 (27) 77 (30) 8 (13) 2 (22) 0 (0) 1 (100) 103 (39) 84 (41) 16 (33) 3 (30) - 0 (0) 0.640
NSAIDS n (%) 4 (1) 3 (1) 0 (0) 1 (11) 0 (0) 0 (0) 34 (12) 25 (12) 9 (18) 0 (0) - 0 (0) 0.345
OW, n (%)*** 10 (3) 8 (3) 1 (2) 1 (11) 0 (0) 0 (0) 19 (7) 17 (8) 1 (2) 1 (10) - 0 (0) 0.384
CWPC, n (%) 2 (1) 0 (0) 0 (0) 1 (11) 0 (0) 1 (100) 25 (9) 22 (10) 2 (4) 1 (10) - 0 (0) 0.421
ATH, n (%) 124 (38) 113 (44) 10 (17) 1 (11) 0 (0) 0 (0) 112 (42) 90 (44) 18 (37) 4 (40) - 0 (0) 0.799
DL, n (%) 40 (12) 36 (14) 4 (7) 0 (0) 0 (0) 0 (0) 56 (21) 43 (21) 9 (18) 3 (30) - 1 (100) 0.491
DM n (%) 18 (5) 17 (7) 1 (2) 0 (0) 0 (0) 0 (0) 50 (19) 42 (20) 6 (12) 2 (20) - 0 (0) 0.519
CLD, n (%)**** 0 (0) - - - - - 17 (6) 13 (6) 3 (6) 1 (10) - 0 (0) 1.000
Pi* protease inhibitor. AAT alpha-1 antitrypsin, n number. * > 40 g ethanol consumed/day. **Current smokers or ex-smokers of >15 packs/year. OW overweight, ***BMI 30 kg/m2. CLD chronic liver disease, ****Mostly,
chronic hepatitis and/or liver cirrhosis. CWPC coal workers’ pneumoconiosis. DM diabetes mellitus. ATH arterial hypertension. NSAIDS chronic intake of non-steroidal anti-inflammatory drugs. TOB tobacco abuse.


















Table 2 PFS, allele type, mean gene frequency and prevalence in both cohorts
Sample (n) PFS Total alleles Allele types (n) Pi*S and Pi*Z mean gene
frequencyin x 1,000 [95% CI]
Hardy-Weinberg
calculated prevalence [1/x]
M S Z Pi*S Pi*Z MM MS MZ SS SZ ZZ
General population (327) 5.4 654 581 63 10 96 [75-122] 15 [8-29] 1.3 6 37 108 339 4,267
Colorectal cancer (267) 5.4 534 473 50 11 94 [71-122] 21 [11-38] 1.3 6 27 114 259 2,357
P-value 0.954 0.639
N number, PFS precision factor score (scale 0-12), CI confidence interval, Pi* protease inhibitor. No significant differences were found in any of the comparisons.
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(p = 0.502) from the comparison of the mean value in
AAT serum concentrations of the whole CRC group and
each CRC stage (I- IV) (Table 5).
Discussion
The only statistically significant finding of the present
study was the markedly higher AAT serum concentrations
in CRC patients than in healthy controls, regardless of
whether their Pi phenotype was normal (Pi*MM) or defi-
cient (Pi*MS, Pi*MZ or Pi*SZ).
The presence of high serum levels of AAT in patients
with CRC was reported more than 35 years ago, and has
even been linked to distant metastases [21]. Subsequently,
other authors have found that serum AAT levels are asso-
ciated with the clinical stage of the disease [22,23]. In
these pioneering studies, the correlation of serum CEA
and serum AAT with the stage of disease were of a very
similar level of statistical significance (p = 0.004 and 0.003,
respectively). Coinciding with these preliminary results, a
more recent study confirmed that serum levels of AAT are
higher in CRC subjects than in controls, and that these
high levels of serum AAT are directly correlated with theTable 3 Mean serum concentration of alpha-1 antitrypsin
in the phenotypes in both cohorts
Sample Mean serum concentration
of alpha-1 antitrypsin (mg/dl)
MM MS MZ SS SZ
General population
N 256 60 9 1 1
Mean 143.8 122.9 90.2 107.5 71.2
SD (20.5) (30.6) (10.7) - -
Range [88-235] [75-202] [75-107] [107.5] [71.2]
Colorectal cancer
N 206 49 10 0 1
Mean 208 167.7 139.2 - 124
SD (60) (40.8) (31.3) - -
Range [105-459] [93-278] [84-183] - [124]
P 0.0001 0.0001 0.001 NA NA
N number, SD standard deviation, NA not applicable. Significant differences
found between MM, MS and MZ.stage of CRC, making it a useful marker for distinguishing
between early and advanced stages of this malignancy
[24]. However, given the necessarily strict criteria, we can-
not yet be certain whether this biomarker is also altered in
patients with other inflammatory or neoplastic diseases.
Apart from CRC, various authors have found signifi-
cantly elevated AAT serum levels in subjects with a range
of cancers, including lung [25-30], liver [31,32], pancreas
[33], prostate [34], cervix [35], ovary [36,37], breast [38],
Hodgkin’s lymphoma [39], larynx and other head and
neck carcinomas [40,41]. The data provided by these stud-
ies taken together suggest that the presence of elevated
serum levels of AAT in patients with any of these types of
carcinomas is related to an invasive growth of these
tumors. However, the low statistical power of the analyses
that is the consequence of the small sample sizes means
that the true value of this biomarker in the diagnosis and
staging of cancers remains to be established.
On the other hand, AAT has been detected in histological
sections of paraffin-embedded biopsy specimens obtained
by endoscopy or surgically resected CRC samples, with a
markedly higher incidence in advanced than in early carcin-
omas. These findings suggest a local production of AAT
by CRC cells that tends to be associated with a more ag-
gressive tumor behavior, more intense local growth and an
increased tendency to metastasize to distant organs [42].
However, AAT overexpression in cancer tissues is not an
exclusive feature of CRC, since it has also been found in
other types of cancers in different organs, including lung
carcinomas [43], hepatocellular carcinomas [44], adeno-
carcinomas of the stomach [45,46], myeloid leukemia cells
[47,48], brain tumors [49], carcinoid tumors, malignant
melanomas, and schwannomas [50]. In vitro production
of AAT by tumor cells themselves also occurs in a variety
of adenocarcinoma, sarcoma, glioblastoma and chordoma
cell lines [51,52]. Based on the results of these studies, the
presence of AAT in tumors has typically been ascribed to
its production by the tumor cells themselves, and patients
with AAT expression in their tumors have been thought
to have a worse prognosis than those without AAT
expression.
However, two recently published studies have provided
results that call into question these previously accepted
concepts. Firstly, a study of tissue expression of AAT in
Table 4 Colorectal cancer anatomical location, TNM stage, treatment and follow-up, in the different AAT-Pi phenotypes
AAT Pi* genotype
Total n (%) Pi*MM n (%) Pi*MS n (%) Pi*MZ n (%) Pi*SZ n (%) P
Location 0.822
Ascending colon 50 (19) 40 (19) 7 (14) 3 (30) 0 (0)
Transverse colon 22 (8) 18 (9) 3 (6) 1 (10) 0 (0)
Descending colon 30 (11) 24 (12) 4 (8) 2 (20) 0 (0)
Sigmoid colon 91 (34) 68 (33) 21 (43) 1 (10) 1 (100)
Rectum 74 (28) 57 (27) 14 (29) 3 (30) 0 (0)
TNM stage 0.409
I 33 (12) 25 (12) 6 (12) 2 (20) 0 (0)
II 124 (47) 92 (44) 29 (59) 2 (20) 1 (100)
III 85 (32) 71 (34) 9 (19) 5 (50) 0 (0)
IV 25 (9) 19 (10) 5 (10) 1 (10) 0 (0)
Treatment
Surgery 255 (96) 197 (95) 47 (96) 10 (100) 1 (100) 1.000
Chemotherapy 79 (30) 63 (30) 10 (20) 6 (60) 0 (0) 0.058
Radiation 43 (16) 31 (15) 9 (18) 3 (30) 0 (0) 0.559
Chemoradiotherapy 20 (8) 16 (8) 3 (6) 1 (10) 0 (0) 0.921
Palliative care 12 (4) 10 (5) 2 (4) 0 (0) 0 (0) NA
Deaths 62 (23) 45 (22) 14 (29) 3 (30) 0 (0) NA
CRC-related 46 (17) 33 (16) 10 (20) 3 (30) 0 (0) NA
Other causes of death: 16 (6) 12 (6) 4 (8) 0 (0) 0 (0) NA
Acute myocardial infarction 3 2 1 NA
Congestive heart failure 1 1 NA
Gastrointestinal bleeding 2 2 NA
Postsurgical sepsis 3 3 NA
Post-chemotherapy sepsis 2 2 NA
Diffuse non-Hodgkin’s lymphoma 1 1 NA
Pulmonary thromboembolism 2 2 NA
Brain stroke 1 1 NA
Hepatic failure liver cirrhosis-related 1 1 NA
TNM tumor stage classification according to primary tumor invasion proof (T), regional lymph nodes involved (N), and presence of distant metastasis (M), NA not applicable.
CRC colorectal cancer. No significant differences were found in any of the comparisons.
Table 5 Comparison of serum concentrations of AAT in the group of patients with colorectal cancer (total and
classified by TNM stages) vs. controls
GP controls CRC TNM stage of CRC cases
Total Total I II III IV
Number of subjects (%) 327 (100) 267 (100) 33 (12) 124 (47) 85 (32) 25 (9)
Mean serum AAT (SD) 138.5 (25.3) 198.1 (58.0) 197.9 (63.0) 194.3 (60.1) 198.9 (55.7) 214.5 (59.3)
P-value A*: <0.001 P-value B**: 0.502
CRC colorectal carcinoma. GP general population. Serum concentration values are expressed in mg/dL. SD standard deviation.
P-value A*: from the comparison of mean values of serum AAT in the control and CRC groups, and between the mean AAT in the control group and the partial
AAT value for each TNM subgroup.
P-value B**: from the comparison of the mean value of the whole CRC group and each CRC stage (I- IV).
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patients with CRC, using a methylation isotope-labeling-
assisted gel-enhanced liquid chromatography-mass spec-
trometry strategy, found that CRC specimens expressed
less AAT in both tissues and serum than did normal
counterparts [53]. This surprising result was supported
by a subsequent study of gastric cancer tissues and adja-
cent normal tissues obtained from surgery, using two-
dimensional differential gel electrophoresis, validating
protein expression by western blot and IHC, which found
AAT to be significantly downregulated in gastric cancer
patients [54]. In vitro comparative analysis of the human
tumors and normal tissues revealed an association be-
tween reduced local AAT expression and more aggressive
tumor growth [55].
Nevertheless, the role that AAT may play in tumor
invasiveness is currently unknown. It has been sug-
gested that since neutrophil elastase is present in colon
carcinoma tissues, and its level is very similar to the
degree of tissue infiltration by neutrophils, it is possible
that an excess of free elastase promotes a favorable host
environment for carcinogenesis [56]. Other authors have
linked carcinogenesis to AAT degradation by matrix me-
talloproteinases activated by neutrophil elastase, cathepsin
G, and proteinase-3 [57], ultimately resulting in the produc-
tion of COOH-terminal fragments, which boosts tumor
growth in vivo [58].
In addition to the markedly elevated AAT serum levels
found in CRC patients compared with controls, other
results of our study merit discussion, even though the
small sample size and the marked deviation from the
mean of some values meant that these differences between
cases and controls were not statistically significant. Briefly,
these findings were as follows: (1) CRC cases in advanced
stages (III and IV) had higher AAT serum concentrations
than those in early stages (I and II); (2) the gene frequency
of the severe deficiency Pi*Z allele, and the prevalence of
the Pi*MZ, Pi*SZ and Pi*ZZ deficiency phenotypes were
higher in CRC patients than in controls; and (3) CRC pa-
tients with the Pi*MZ genotype tended to develop more
locally advanced tumors, had a greater need for postoper-
ative chemotherapy, and had a greater rate of mortality
from causes directly related to the CRC than did subjects
with the MM genotype.
Nonetheless, our results cast some doubt on the accur-
acy of the present study, because it might be biased by the
small size of the samples studied, as suggested by the low
PFS displayed by the two cohorts (both 5.4 points). This
low value would require both samples to be approximately
doubled in size to improve it sufficiently.
There is wide-ranging evidence about the relationship
between AAT deficiency and the development of various
types of malignancy, including CRC. The level of evidence,
in terms of evidence-based medicine, is high with respectto the risk of subjects with Pi*ZZ genotype developing
hepatocellular carcinomas, which reaches the very high
percentage of 28% [1,4,5]. Regarding lung cancer, two
studies found Pi*MS and Pi*MZ heterozygote individuals
to be at increased risk of developing bronchial carcinomas,
particularly of the squamous and bronchoalveolar cell
types, independent of smoking habit and presence of
COPD [6,7]. The mechanism involved in lung carcino-
genesis would be an excess of neutrophil elastase that
is not neutralized by AAT and that stimulates develop-
ment, invasion and metastasis. This same mechanism
would probably be shared by all other types of cancers,
including CRC [8,9]. There is also some evidence of a
relationship between AAT deficiency and the development
of neoplasms of the urinary bladder and gallbladder, and
malignant lymphomas [10-12].
Colorectal cancer, a leading cause of cancer deaths
worldwide, has also been associated with AAT deficiency
[13,14]. It is known that both normal and cancer intestinal
cells secrete AAT [56,59] to neutralize elastase, which is
present in high concentrations in colon carcinoma cells,
in an attempt to maintain the protease-antiprotease
balance. This prevents the activation of procathepsin B
and proprotein convertase, and reduces the production
of TNF-α and IL-1a, which prevents liver metastases
[60-62]. However, the only two clinico-epidemiological
studies carried out to date produced conflicting results
[13,14]. The first study, of patients with CRC and a
microsatellite instability genotype, found a significantly
higher prevalence of AAT deficiency alleles in CRC
subjects than in the general population (21.6% vs. 9.4%),
and that smokers with AAT deficiency had a 20-times
greater risk than expected of developing high microsatel-
lite instability compared with smokers without AAT defi-
ciency [13]. Conversely, a more recent case-control study
confirmed the link between smoking history and the high
degree of microsatellite instability, but no difference in
AAT deficiency frequency between cases and controls,
irrespective of their microsatellite unstable subtype [14].
Conclusions
Our study found that patients with CRC have much
higher serum AAT concentrations than healthy controls,
regardless of the genotypes of the subjects. This finding
is consistent with most published classic studies, but is
unlike others published recently. Its meaning is therefore
uncertain, and its potential role in the diagnosis and
staging of CRC remains to be established. Further studies
are needed in other diseases and other gastrointestinal
tumors to determine the sensitivity and specificity of this
biomarker.
On the other hand, based on our findings, our initial
hypothesis that AAT deficiency is involved in the develop-
ment and progression of CRC could neither be confirmed
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ficiency with more advanced tumor stage was observed.
Not enough Z alleles were analyzed in our study for statis-
tical significance to be reached for an effect size of the ob-
served magnitude. Similar studies but of greater statistical
power are therefore required to settle this matter.
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